ATE363535T1 - Stabile bakterizide proteine, welche die permeabilität erhöhen und pharmazeutische zusammensetzungen, diese enthaltend - Google Patents

Stabile bakterizide proteine, welche die permeabilität erhöhen und pharmazeutische zusammensetzungen, diese enthaltend

Info

Publication number
ATE363535T1
ATE363535T1 AT03000252T AT03000252T ATE363535T1 AT E363535 T1 ATE363535 T1 AT E363535T1 AT 03000252 T AT03000252 T AT 03000252T AT 03000252 T AT03000252 T AT 03000252T AT E363535 T1 ATE363535 T1 AT E363535T1
Authority
AT
Austria
Prior art keywords
residue
pharmaceutical compositions
compositions containing
containing same
increase permeability
Prior art date
Application number
AT03000252T
Other languages
English (en)
Inventor
Georgia Theofan
Arnold Horwitz
David Burke
Manik Baltaian
Lynn Grinna
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Application granted granted Critical
Publication of ATE363535T1 publication Critical patent/ATE363535T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
AT03000252T 1993-02-02 1994-02-02 Stabile bakterizide proteine, welche die permeabilität erhöhen und pharmazeutische zusammensetzungen, diese enthaltend ATE363535T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/013,801 US5420019A (en) 1993-02-02 1993-02-02 Stable bactericidal/permeability-increasing protein muteins

Publications (1)

Publication Number Publication Date
ATE363535T1 true ATE363535T1 (de) 2007-06-15

Family

ID=21761817

Family Applications (3)

Application Number Title Priority Date Filing Date
AT94908704T ATE196650T1 (de) 1993-02-02 1994-02-02 Stabile bakterizide proteine, welche die permeabilität erhöhen und pharmazeutische zusammensetzungen, diese enthaltend
AT03000252T ATE363535T1 (de) 1993-02-02 1994-02-02 Stabile bakterizide proteine, welche die permeabilität erhöhen und pharmazeutische zusammensetzungen, diese enthaltend
AT00103901T ATE230797T1 (de) 1993-02-02 1994-02-02 Stabile produkte des bakterientötenden/durchlässigkeiterhöhenden proteins (pbi) und diese enthaltende arzneimittelzusammensetzungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94908704T ATE196650T1 (de) 1993-02-02 1994-02-02 Stabile bakterizide proteine, welche die permeabilität erhöhen und pharmazeutische zusammensetzungen, diese enthaltend

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00103901T ATE230797T1 (de) 1993-02-02 1994-02-02 Stabile produkte des bakterientötenden/durchlässigkeiterhöhenden proteins (pbi) und diese enthaltende arzneimittelzusammensetzungen

Country Status (18)

Country Link
US (6) US5420019A (de)
EP (3) EP1013760B1 (de)
JP (4) JP4139867B2 (de)
KR (1) KR100361997B1 (de)
CN (1) CN1142996C (de)
AT (3) ATE196650T1 (de)
AU (1) AU693089B2 (de)
CA (1) CA2155004C (de)
DE (3) DE69426019T2 (de)
DK (2) DK1310558T3 (de)
ES (2) ES2150983T3 (de)
FI (3) FI112367B (de)
GR (1) GR3034492T3 (de)
NO (3) NO315705B1 (de)
NZ (1) NZ262284A (de)
PT (2) PT1310558E (de)
WO (1) WO1994018323A1 (de)
ZA (1) ZA94703B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US6265187B1 (en) * 1989-02-14 2001-07-24 Incyte Pharmaceuticals, Inc. Recombinant endotoxin-neutralizing proteins
US6811989B1 (en) * 1989-02-17 2004-11-02 Bayer Corporation Pancreatic islet cell antigens obtained by molecular cloning
US5840836A (en) * 1989-02-17 1998-11-24 Bayer Corporation Pancreatic islet cell antigens obtained by molecular cloning
US6274348B1 (en) 1992-05-19 2001-08-14 Xoma Corporation Methods for the preparation of positively charged proteins
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
MX9401807A (es) * 1993-03-12 1995-01-31 Xoma Corp Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas.
US5858974A (en) * 1995-07-20 1999-01-12 Xoma Corporation Anti-fungal peptides
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
WO1995000641A1 (en) 1993-06-17 1995-01-05 Xoma Corporation Lipopolysaccharide binding protein derivatives
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
DE69430823T2 (de) * 1993-09-22 2003-02-20 Xoma Technology Ltd., Berkeley Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
DE69526216T2 (de) * 1994-01-14 2002-11-14 Xoma Technology Ltd., Berkeley Antifungaleverfahren und mitteln
PT754050E (pt) * 1994-01-14 2002-11-29 Xoma Technology Ltd Metodos e materiais contra bacterias gram-positivas
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
WO1996014428A1 (en) * 1994-11-08 1996-05-17 Novagen, Inc. Method for in vitro protein synthesis
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
WO1997017990A1 (en) * 1995-11-14 1997-05-22 Xoma Corporation Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury
US5856159A (en) * 1996-03-27 1999-01-05 Cytel Corporation Production of galactosyltransferase
US5741779A (en) 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
JP2000510845A (ja) * 1996-05-10 2000-08-22 ゾーマ コーポレイション ヒト髄膜炎菌血症のためのｂｐｉタンパク質産物の治療用途
JP2000511190A (ja) * 1996-05-23 2000-08-29 ゾーマ コーポレイション 外傷に起因する出血に見舞われたヒトにおけるｂｐｉタンパク質産物の治療用途
EP0939766A2 (de) 1996-05-24 1999-09-08 The Regents Of The University Of Minnesota Synthese von löslichen beta-sheet bildenden peptiden
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
CN1062564C (zh) * 1996-12-20 2001-02-28 周红 猪血中提纯杀菌性/通透性增加蛋白的方法
EP0973886B1 (de) * 1997-01-24 2005-03-23 AVI BioPharm, Inc. Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
FR2767323B1 (fr) * 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6156514A (en) * 1998-12-03 2000-12-05 Sunol Molecular Corporation Methods for making recombinant cells
US6242219B1 (en) 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
US7041644B2 (en) * 1999-04-01 2006-05-09 Xoma Technology Therapeutic uses of BPI protein products in BPI-deficient humans
US6153584A (en) * 1999-04-01 2000-11-28 Levy; Ofer Therapeutic uses of BPI protein products in BPI-deficient humans
US6759241B1 (en) 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist
JP2004517865A (ja) * 2000-12-01 2004-06-17 ゾーマ テクノロジー リミテッド Ｂｐｉタンパク質産物またはｂｐｉインヒビターを使用する、周皮細胞増殖の調節
US20030049616A1 (en) * 2001-01-08 2003-03-13 Sydney Brenner Enzymatic synthesis of oligonucleotide tags
AU2002248557A1 (en) * 2001-03-05 2002-09-19 Transtech Pharma, Inc. High level insect expression of rage proteins
WO2003070751A2 (en) 2002-02-20 2003-08-28 Regents Of The University Of Minnesota Partial peptide mimetics and methods
WO2003083066A2 (en) * 2002-03-27 2003-10-09 Immunex Corporation Methods for increasing polypeptide production
ATE496134T1 (de) 2002-03-29 2011-02-15 Xoma Technology Ltd Multigene vectoren und methoden für eine erhöhte expression von rekombinanten polypeptiden
US7906722B2 (en) * 2005-04-19 2011-03-15 Palo Alto Research Center Incorporated Concentrating solar collector with solid optical element
EP1741440A1 (de) 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
MX2010003622A (es) 2007-10-12 2010-04-14 Hoffmann La Roche Expresion proteinica a partir de acidos nucleicos multiples.
CN103648515B (zh) 2011-04-05 2018-01-02 达纳-法伯癌症研究所有限公司 作为辐射缓和剂和辐射防护剂的bpi和其同源物
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
CN110402253B (zh) 2017-03-10 2024-01-05 豪夫迈·罗氏有限公司 用于生产多特异性抗体的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4816566A (en) * 1983-06-01 1989-03-28 Hoffmann-La Roche, Inc. Polypeptides having interferon activity
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
EP1659132A1 (de) * 1987-08-11 2006-05-24 New York University BPI Fragmente
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5770694A (en) * 1990-08-13 1998-06-23 Incyte Pharmaceuticals, Inc. Genetically engineered BPI variant proteins
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
WO1994025476A1 (en) * 1993-04-30 1994-11-10 Incyte Pharmaceuticals, Inc. Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
AU9127591A (en) * 1990-12-03 1992-06-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
JPH07502642A (ja) * 1991-09-26 1995-03-23 インサイト　ファーマシューティカルズ，インコーポレイテッド 新規な形態のリポ糖結合性タンパク質（ｌｂｐ）
BR9205419A (pt) * 1991-10-31 1994-04-19 Kwang Sil Lee Sistema de identificacao eletronica tendo capacidade de resposta remota automatica e processo de controle de identificacao automatica para o mesmo
ATE178652T1 (de) * 1992-05-19 1999-04-15 Xoma Corp Verbessertes verfahren zur herstellung von endotoxinbindungsproteinen
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
EP0690721B1 (de) * 1993-03-12 1998-05-13 Xoma Corporation Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
AU694108B2 (en) * 1993-03-12 1998-07-16 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
MX9401807A (es) * 1993-03-12 1995-01-31 Xoma Corp Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas.

Also Published As

Publication number Publication date
US6828418B2 (en) 2004-12-07
EP1310558B1 (de) 2007-05-30
US20060009383A1 (en) 2006-01-12
DE69434980T2 (de) 2008-01-24
KR960700340A (ko) 1996-01-19
EP1013760A2 (de) 2000-06-28
DK1310558T3 (da) 2007-10-08
KR100361997B1 (ko) 2003-04-08
US5674834A (en) 1997-10-07
JP2004254697A (ja) 2004-09-16
WO1994018323A1 (en) 1994-08-18
DE69426019D1 (de) 2000-11-02
EP1013760A3 (de) 2000-08-09
US5827816A (en) 1998-10-27
NZ262284A (en) 1997-11-24
EP0689592B1 (de) 2000-09-27
NO20023224D0 (no) 2002-07-03
DE69431995D1 (de) 2003-02-13
DE69434980D1 (de) 2007-07-12
FI115633B (fi) 2005-06-15
NO20023224L (no) 1995-10-02
DK0689592T3 (da) 2000-10-16
EP1013760B1 (de) 2003-01-08
CA2155004C (en) 2010-03-30
EP0689592A1 (de) 1996-01-03
FI953658L (fi) 1995-09-07
ES2288199T3 (es) 2008-01-01
US5420019A (en) 1995-05-30
ES2150983T3 (es) 2000-12-16
ATE230797T1 (de) 2003-01-15
NO315705B1 (no) 2003-10-13
CA2155004A1 (en) 1994-08-18
CN1142996C (zh) 2004-03-24
JPH08506586A (ja) 1996-07-16
FI953658A0 (fi) 1995-08-01
EP1310558A2 (de) 2003-05-14
FI20050243L (fi) 2005-03-07
NO20050998L (no) 1995-10-02
JP2004024276A (ja) 2004-01-29
JP4139867B2 (ja) 2008-08-27
ZA94703B (en) 1994-09-05
HK1014548A1 (en) 1999-09-30
EP1310558A3 (de) 2003-08-13
CN1120352A (zh) 1996-04-10
FI20031199A7 (fi) 2003-08-26
JP2006321813A (ja) 2006-11-30
US20030109436A1 (en) 2003-06-12
GR3034492T3 (en) 2000-12-29
PT1310558E (pt) 2007-09-07
US6433140B1 (en) 2002-08-13
AU6170294A (en) 1994-08-29
NO319156B1 (no) 2005-06-27
PT689592E (pt) 2001-03-30
DE69431995T2 (de) 2003-11-13
NO953033D0 (no) 1995-08-01
ATE196650T1 (de) 2000-10-15
FI20050243A7 (fi) 2005-03-07
NO20050998D0 (no) 2005-02-24
AU693089B2 (en) 1998-06-25
NO953033L (no) 1995-10-02
DE69426019T2 (de) 2001-05-17
FI112367B (fi) 2003-11-28

Similar Documents

Publication Publication Date Title
ATE196650T1 (de) Stabile bakterizide proteine, welche die permeabilität erhöhen und pharmazeutische zusammensetzungen, diese enthaltend
FI860153A0 (fi) Oligopeptider, deras mellanprodukter och foerfarande foer deras framstaellning.
AU6701890A (en) Process for the production of biologically active protein
NO20073914L (no) Biologisk aktive peptider
DE59108947D1 (de) Neues menschliches, rekombinantes interferon gamma

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1310558

Country of ref document: EP

REN Ceased due to non-payment of the annual fee